METHOD OF ADMINISTRATION OF IGF-I

Abstract: A method is disclosed that comprises administering insulin-like growth factor-I (IGF-I) to a mammal so as to sustain its biological activity in the mammal comprising administering a therapeutically effective amount of IGF-I to the mammal to provide an exposure to IGF-I for a period of time that stimulates the maximum biological response in the mammal, then discontinuing said administration for a period of time equal to or less than the time period used for administration, and repeating this pattern of administration and discontinuance of administration for a period as long as necessary to achieve or maintain the desired biological response in the mammal.

Description: METHOD OF ADMINISTRATION OF IGF-I Background of the Invention Field of the Invention This invention relates to a method of dosmg and administering IGF-I in an intermittent fashion such that the maximum favorable biological activity of IGF-I is achieved and maintained in the treatment of chronic disorders with minimized unfavorable side effects Descπption of Related Disclosures Human insulin-like growth factor-I (IGF-I) is a 7649-dalton polypeptide with a pi of 84 [Rinderknecht andHumbel Proc Natl Acad Sci USA. 73 2365 (1976), Rinderknecht and Humbel, J Biol Chem . 253 2769 ( 1978)] belonging to a family of somatomedins with insulin-like and mitogenic biological activities that modulate the action of growth hormone (GH) Van Wyk et al , Recent Prog Horm Res . 30 259 (1974), Binoux, Ann Endocπnol .41 157 (1980). Clemmons and Van Wyk. Handbook Exp Pharmacol . 57 161 (1981), Baxter, Adv. Chn Chem . 25 49 (1986), U S Pat No 4,988,675, WO 91/03253, and WO 93/23071 IGF-I has hypoglycemic effects similar to insulin but also promotes positive nitrogen balance Underwood et al , Hormone Res . 24 166 (1986), Guler et al , N Engl J Med . 317 137 (1987) Due to this range of activities, IGF-I is bemg tested in humans for uses ranging from wound healing to the reversal of whole body catabohc states to treatment of heart conditions such as congestive heart failure Guler et al , Proc Natl Acad Sci USA. 85 4889 (1988), Duerr et al , J Chn Invest . 95 619-627 (1995) IGF-I is also bemg tested m the clinic for treating diabetes U S Pat Nos 5,273,961 , 5,126,324, 5,187,151 , 5,202,119, 5,374,620, 5,106,832, 4,988,675, 5,106,832, 5,068,224, 5,093,317, and 4,876,242 and WO 92/11865 and WO 94/16722 disclose various methods of treating patients using IGF-I A general scheme for the etiology of some clinical phenotypes which give πse to insulin resistance and the possible effects of administration of IGF-I on selected representative subjects is given m several references See, e g , Elahi et al , "Hemodynamic and metabolic responses to human insulin-like growth factor- 1 (IGF-1) m men," m Modem Concepts of Insulm-Like Growth Factors. (Spencer, EM, ed ), Elsevier, New York, pp 219- 224 (1991), Quinn et al , N Engl J Med . 323 1425-1426 (1990), Schalch et al , "Short-term metabolic effects of recombinant human insulin-like growth factor 1 (rhIGF-1) in type 11 diabetes melhtus," in Modem Concepts of Insulin-Like Growth Factors. (Spencer, EM, ed ), Elsevier, New York, pp 705-714 (1991), Schoenle et al , Diabetologia. 34 675-679 (1991), Usala et al , N Engl J Med . 327 853-857 (1992), Lieberman et al , J Chn Endo Metab . 75 30-36 (1992), Zenobi et al . J Chn Invest . 90 2234-2241 (1992), Zenobi et al . J Clm Invest.89 1908-1913 (1992). Keiref al . J C n Invest . 91 141-147 (1993), and U S Pat No 4,988,675 WO 94/16722 discloses a method of chrome modification of cell bamer properties by exposmg a cell to a modification-effective amount of IGF-I for at least about seven days and a method of chronic amelioration or reversal of insulin resistance However, when IGF-I was used to treat type II diabetes patients m the clinic at a dose of 120-160 μg/kg twice daily, the side effects outweighed the benefit of the treatment Jabπ et al , Diabetes. 43 369-374 (1994) See also Wilton, Acta Paediatr . 383 137-141 (1992) regarding side effects observed upon treatment of patients with IGF-I IGF-I has also been found to exert a variety of actions in the kidney Hammerman and Miller, Am J Phvsiol . 265 F1-F14 (1993) It has been recognized for decades that the mcrease m kidney size observed in patients with acromegaly is accompanied by a significant enhancement of glomerular filtration rate O'Shea and Lavish. J Am Soc Nephrol . 3 157-161 (1992) U S Pat No 5,273,961 discloses a method for prophylactic treatment of mammals at nsk for acute renal failure Infusion of the peptide m humans with normal renal function increases glomerular filtration rate and renal plasma flow Guler et al , Acta Endocπnol . 121 101 - 106 (1989). Guler er a/ . Proc Natl Acad Sci USA. 86 2868-2872 . 1989 * 1. Hirschberg et al . Kidnev Int . 43 387- 397 (1993), U S Pat No 5,106,832 Further, humans with moderately reduced renal function respond to short- term (four days) IGF-I administration by increasing their rates of glomerular filtration and renal plasma flow Hence, IGF-I is a potential therapeutic agent in the setting of chronic renal failure O'Shea et al , Am J Phvsiol . 264 F917-F922 (1993) Additionally, renal function can be enhanced over a period of days by the admmistration of IGF-I m the setting of end-stage chrome renal failure This is important, smce end-stage chrome renal failure is a condition that can only be treated with dialysis or transplantation and the mcidence thereof is rapidly increasing Diabetics and the elderly tend to have this condition Approximately sixty percent of patients with end-stage chronic renal failure are on hemodialysis, about ten percent are on peπtoneal dialysis, and the remaining about thirty percent receive a transplant Dialysis therapy is imtiated in over 50,000 patients each year in the Umted States An additional 25% of patients who have reached end-stage renal failure are demed access to dialysis each year The cost of caring for these patients on dialysis currently averages over $200 million a month Furthermore, the patients exhibit an impaired lifestyle on dialysis Despite the fact that IGF-I can enhance renal function for those experiencing end-stage chrome renal failure, the enhancements of the glomerular filtration rate and renal plasma flow mduced by IGF-I short-term do not persist duπng long-term admmistration and mcidence of side-effects is high Miller et al , Kidnev International.46 201 -207 ( 1994) The dynamics of IGF-I mteraction with sensitive tissues are complex and incompletely understood Biological activity of circulating IGF-I is regulated by levels of plasma IGFBPs, which both enhance and inhibit IGF-I actions Cohick and Clemmons, Annu Rev Phvsiol . 55 131 -153 (1993), Kupfer et al , J Clin Invest . 21 391-396 (1993) In addition, IGFBPs present m tissues regulate the mteraction of circulating IGF-I with its receptor Tissue IGF-I receptor density is altered by changes in levels of circulating IGF-I In kidney, the numbers of IGF-I receptors are inversely related to levels of circulating IGF-I Hise et al , Clm Sci . 83 223- 239 (1991) It is known that under some circumstances elevated levels of circulating IGF-I are associated with or directly causative of long-term changes m renal function For example, the enhancements of inulin and PAH clearances that accompany the elevations of circulating GH and IGF-I m patients with acromegaly are sustained over years of time Hckos et al , Acta Endocπnol . 2J. 226-236 (1956) An increase in creatinine clearance occurred within the first 12 days of IGF-I administration to a GH-insensitive Laron dwarf The increase was progressive over the next 59 days Walker et al , J Pediatr . 121 641-646 (1992) GH stimulates the synthesis of IGFBP3 m liver Hammerman and Miller, supra, Cohick and Clemmons, supra, Kupfer et al , supra It is the reduction in levels of circulating GH resulting from IGF-I inhibition of pituitary GH release that is thought to result m the fall of circulating IGFBP3 m humans administered IGF-I Because of their GH lnsensitivity, IGFBP3 levels are low and are mcreased by IGF-I m Laron dwarfs Kenety et al , Acta Endocπnol . 128 144-149 (1993) This difference or another m the IGF-I effector system could explain the absence of refractoriness to IGF-I in these individuals Walker et al , supra, found that IGF-I increased uπnarv calcium excretion or urinary volume Miller et al , supra, did not see such effect IGF-I a enhances the transport of phosphate across the proximal tubular brush border membrane Quigley and Baum, J Clm Invest . 88 368-374 (1991) Patients with long-standing acromegaly showed marked renal hypertrophy and had supranormal glomerular filtration rates, suggestmg that the hyperfiltration that accompanies long-standing elevations of circulating GH and IGF-I in humans is not mjuπous to the kidney D kos et al . supra. Hoogenberg et al . Acta Endocπnol . 129 151-157 (1993) For complete reviews of the effect of IGF-I on the kidney, see, e g , Hammerman and Miller, Am J Phvsiol .265 F1-F14 (1993 * ) and Hammerman and Miller. J Am Soc Nephrol . 5 1-11 (1994) As to anabolic indications for IGF-I, m HI V-infected patients treated consecutively with IGF-I, the IGF- I promoted anabolism but tachyphylaxis developed rapidly m the patients Lieberman et al , U S Endocπne Meeting. June 1993 (Abst 1664), disclosed more fully by Lieberman et al , J Clm Endo Metab . 78 404-410 (1994) In patients with severe head lnjunes, a condition associated with profound hypercatabohsm and nitrogen loss, infusion of IGF-I produced only a transient positive nitrogen balance In the first week the patients expeπenced a positive nitrogen balance, but duπng the second week, a negative nitrogen balance developed Chen et al , U S Endocπne Meeting. June 1993 (Abst 1596) All of these studies indicate that there is a need m the art for a treatment with IGF-I that does not subside after a certain peπod of treatment time and one that both maximizes efficacy and minimizes the side effects of IGF-I Summary of the Invention Accordingly, this mvention supplies a method for admmistermg IGF-I to a mammal m an intermittent fashion so as to sustain its biological response in the treatment of a chrome disorder in the mammal compπsmg adm isteπng a therapeutically effective amount of IGF-I to the mammal to provide an exposure to IGF-I for a peπod of time that provides the maximum biological response in the mammal, then discontinumg said admmistration for a peπod of time equal to or less than the time peπod duπng which the IGF-I was previously admmistered, then admmistermg a therapeutically effective amount of IGF-I to the mammal to provide an exposure to IGF-I for a penod of time that provides the maximum biological response m the mammal, then discontinumg said admmistration for a peπod of time equal to or less than the time peπod duπng which the IGF-I was just previously admmistered, and repeating this pattern of admmistration and discontinuance of administration for as long as necessary to achieve or maintain sustained biological response in the mammal In a preferred embodiment, the chrome disorder is chrome renal failure, diabetes, a cardiac disorder such as congestive heart failure, an anabolic disorder, an lmmunological disorder, a neurological disorder, or a combination of such disorders In another aspect, this mvention supplies a method for treating chrome renal failure m a mammal by treating with IGF-I m an intermittent fashion compπsmg admmistermg a therapeutically effective amount of IGF-I to the mammal to provide an exposure to IGF-I for from about three to twelve days, then discontinuing said admmistration for from about two to seven days, then admmisteπng a therapeutically effective amount of IGF-I to the mammal to provide an exposure to IGF-I for from about three to twelve days, then discontinuing said administration for from about two to seven days, and repeating this pattern of administration and discontinuance of administration for as long as necessary to achieve or maintain sustained renal function in the mammal, said time peπods of discontinumg admmistration bemg for a peπod of time equal to or less than the time peπod duπng which the IGF-I was just previously admmistered Bπef Descπption of the Drawings Figure 1 depicts inulin clearance for five patients as a function of days m the study Figure 2 depicts PAH clearance for five patients as a function of days in the study Figure 3 depicts IGF-I levels for five patients as a function of days m the study (normal is 135-449 ng/mL) Figure 4 depicts IGFBP3 levels for five patients as a function of days in the study (normal is 1 9-3 6 mg/L) Figure 5 depicts IGFBP1 levels for five patients as a function of days in the study (normal is 10-150 ng/mL) Figure 6 depicts IGFBP2 levels for five patients as a function of days in the study (normal is 225-1038 ngmL) Figure 7 depicts mulm clearance m Patient 2 as a function of days m the study and weeks m the study Figure 8 depicts mulm clearance m Patient 3 as a function of days in the study and weeks m the study Figure 9 depicts mulm clearance m Patient 4 as a function of days m the study and weeks m the study Figure 10 depicts mulm clearance m Patient 5 as a function of days m the study and weeks in the study Figure 1 1 depicts mulm clearance for five patients as a function of days in the study and weeks m the study Detailed Descπption of the Preferred Embodiments Definitions As used herem, "biological response" refers to the favorable response of a mammal having a specific chronic disorder to treatment with IGF-I Maximizing the response means improving efficacy but at the same time avoiding or at least minimizing the occurrence of side effects The response is tailored to the disorder bemg treated Thus, for example, "biological response" m the context of end-stage chrome renal failure, or "improved kidney function" refers to delaymg the time a patient has to go on dialysis by at least one month "Biological response" in the context of diabetic indications refers to decreasing a mammal's blood sugar levels, and reducmg markers of glycemic control such as hemoglobin Al c In the context of anabolic disorders, the phrase refers to increasing anabolic parameters and clinical phenotypes In the context of cardiac disorders, the phrase refers to improvement m cardiac ftmction "Sustamed biological response" refers to mamtainmg the biological response (without substantial side effects) for an extended peπod of time as is considered appropπate for the disorder in question A "peπod that provides the maximum biological response" refers to a time peπod representing the maximum time required to obtain and maintain, or to stimulate, the favorable biological response m the mammal This amount of time will depend, for example, on the type of mammal bemg treated, the type of disorder bemg treated, and the dose bemg admmistered (to avoid side-effects) Preferably, this amount will be m the range of from about three to twelve days, more preferably three to five days or seven to twelve days, when the treatment cycle is a total of seven days or 14 days, respectively "Provide an exposure to IGF-I" refers to an exposure that is continuous or m consecutive days (at least once a day consecutively) over the penod of days specified This may be accomplished, for example, by daily or twice daily injections, or by long-actmg formulations of IGF-I that are taken once but provide contmuous exposure of the mammal to the IGF-I for the duration of the desired exposure penod of the treatment The discontinuance of treatment for injections of at least daily frequency is a contmual or daily consecutive lack of treatment for the peπod specified The discontinuance of treatment for long-actmg formulations begins when the blood levels of IGF-I have fallen below the desired or maximum level for efficacious treatment and ends when the IGF-I is agam admmistered to the mammal "Treatment" refers to both therapeutic treatment and prophylactic or preventative measures Those m need of treatment mclude those already with the disorder as well as those prone to havmg the disorder or diagnosed with the disorder or those in which the disorder is to be prevented "Consecutive" treatment or admmistration refers to treatment on at least a daily basis without mterraption m treatment by one or more days "Intermittent" treatment or admmistration, or treatment or admmistration m an "intermittent" fashion refers to treatment that is not consecutive, but rather cyclic m nature The treatment regime herem mvolves short-term admmistration on an intermittent basis as part of a single, long-term course of treatment One method of judging the correct intermittent regimen for a particular indication of use is to administer IGF-I by daily mjection until the time of the maximal effect of the drag is obtamed and before the biological response wanes or until side effects occur to any significant degree, whichever occurs earlier This is the most suitable peπod of treatment as defined herem The maximum peπod of rest from treatment will be an equivalent, or more usually a lesser, interval of time Hence, the two gauges of the intermittent regime that is most appropπate are the maximum efficacy observed and the occurrence of side effects, with the treatment bemg tailored to minimize the side effects seen m a particular disease state "Side effects" refer to effects of treatment with IGF-I that are not the intended effects such as, e.g., cardiac effects including syncopal episodes with lightheadedness, fainting and seizure activity, bradycardia associated with nausea and dizziness, transient atπal fibnllation, hypoglycemia, and asymptomatic tachycardia Other side effects mclude Bell's palsy, lntracranial hypertension, papilledema, hypokalemia, mild weight gam, dyspnea, bilateral jaw tenderness, orthostatic hypotension, local bummg or pam at the mjection site, headaches including migraine headaches, abdominal pam, sinusitis, jaw pam, edema, paratid swelling, myalgias, arthralgias, fatigue, weakness, snoring, breast enlargement, back pam, flushing, difficulty breathing, transient hypertension, kidney stones, and coarsing of facial features Effects on breathing mclude tonsillar and adenoidal enlargement and acute pulmonary edema, and adverse effects on blood cells mclude thrombocytopemic purpura and neutropenia As used herem "chrome" refers to a disorder that is not acute but rather occurs more or less on a continuous level A "disorder" is any condition that would benefit from treatment with IGF-I, including but not limited to, for example, chrome lung disease, hyperglycemic disorders as set forth below, chrome renal disorders, such as chrome renal insufficiency, end-stage chrome renal failure, glomerulonephπtis, interstitial nephπtis, pyelonephπtis, glomerulosclerosis, e.g., Kimmelsuel-Wilson m diabetic patients and kidney failure after kidney transplantation, obesity, GH-insufficiency, Turner's syndrome, Laron's syndrome, short stature, undesirable symptoms associated with aging such as increasing lean mass-to-fat ratios, lmmunological disorders such as immunodeficiencies mcludmg decreased CD4 counts and decreased immune tolerance or chemotherapy-induced tissue damage, bone marrow transplantation, diseases or insufficiencies of cardiac structure or function such as chronic heart conditions and congestive heart failure, chrome neuronal, neurological, or neuromuscular disorders, e g , peπpheral neuropathy, multiple sclerosis, myotonic dystrophy, catabohc states associated with wasting caused by any condition, mcludmg, e g , trauma or wounding or infection such as with a bactenum or human virus such as HIV, Laron dwarfism, wounds, skin disorders, gut structure and function that need restoration, and so forth The disorder bemg treated may be a combination of two or more of the above disorders For purposes herem, "hyperglycemic disorders" refers to all foπns of diabetes, such as type I and type II diabetes, as well as hypeπnsulmemia and hyper pidemia, e g , obese subjects, and insulin-resistant diabetes, such as Mendenhall's Syndrome, Werner Syndrome, leprechaunism, lipoatrophic diabetes, and other lipoatrophies The preferred hvperglycemic disorder is diabetes especially type II diabetes "Long-acting formulations" of IGF-I refer to formulations that mamtam levels of exogenously admmistered IGF-I m the blood for an extended penod of time, generally beyond one day, so that mjections need not be given on a daily basis Long-actmg formulations mclude, for example, sustained-release formulations, IGF-I that is PEGylated, and IGF-I formulated or complexed with an IGF binding protem "Mammal" for purposes of treatment refers to any animal classified as a mammal, mcludmg humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, sheep, pigs, cows, etc Preferably, the mammal herem is human As used herem, "IGF-I" refers to insulin-like growth factor-I from any species, mcludmg bovme, ovme, porcine, equine, avian, and preferably human, m native-sequence or m vaπant form, and from any source, whether natural, synthetic, or recombinant IGF-I has been isolated from human serum and produced recombmantly See, e g , EP 123,228 and 128,733 Preferred herem for human use is human native-sequence, mature IGF-I, more preferably without a N- teπnmal methionine, prepared, e g , by the process descπbed in EP 230,869 published August 5, 1987, EP 128,733 published December 19, 1984, or EP 288,451 published October 26, 1988 More preferably, this native- sequence IGF-I is recombmantly produced and is available from Genentech, Ine , South San Francisco, CA for clinical investigations The preferred IGF-I vaπants are those descπbed m U S Pat No 5,077,276, WO 87/01038, and WO 89/05822, / e , those wherem at least the glutamic acid residue is absent at position 3 from the N-terminus of the mature molecule or those having a deletion of up to five ammo acids at the N-terminus The most preferred vaπant has the first three ammo acids from the N-terminus deleted (vaπously designated as brain IGF, tIGF-I, des(l-3)-IGF-I, or des-IGF-I) Modes for Carrying out the Invention The IGF-I is admmistered to the mammal by any suitable technique, depending mainly on the nature of the disorder and type of mammal, mcludmg parenterally, mtranasally, mtrapulmonary, orally, or by absorption through the skin It can be admmistered locally or systemically Examples of parenteral administration mclude subcutaneous, intramuscular, intravenous, mtraarteπal, and intrapeπtoneal admmistration This mcludes mjections (smgle or multiple, e g , 1-4 per day) or infusions Preferably, the IGF-I is admmistered by daily or twice daily subcutaneous mjections or by subcutaneous or intravenous infusion The IGF-I to be used m the therapy will be formulated and dosed m a fashion consistent with good medical practice, taking mto account the clinical condition of the individual patient (especially the side effects of treatment with IGF-I as noted above), the site of delivery of the IGF-I composition, the method of administration, the schedulmg of admmistration, and other factors known to practitioners The mcidence of side effects of IGF-I may be reduced bv decreasmg the dose Kupfer et al , supra, Hartman et al , J Clm Invest . 91 2453-2462 (1993) The "effective amount" of K for purposes herem is thus determined by such considerations and is an amount that mcreases and mamtams the relevant, favorable biological response of the mammal As a general proposition, the total pharmaceutically effective amount of IGF-I admmistered parenterally per dose will be m the range of about 5 to 1000 μg kg/day, preferably 10 to 500 μg/kg/day, more preferably about 30 to 200 μg/kg/day, of patient body weight, although, as noted above, this will be subject to a great deal of therapeutic discretion For example, with treatment of chrome renal failure, the dose per dav is preferably about 10 to 160 μg/kg, more preferably 20 to 100 μg kg, and most preferably about 25 to 75 μg/kg The peπod of treatment with IGF-I is that which provides a maximum biological response as defined above, preferably about 3 to 12 days, more preferably 3-8 days, most preferably 4-7 days, and the off-treatment peπod is about 2-10 days, more preferably 2-8 days, most preferably 2-7 days In a particularly preferred embodiment, the on-treatment peπod is about 3-5 days for a 7-day cycle and about 7-12 days for a 14-day cycle, and the off-treatment penod is about 2-4 days for a 7-day cycle and about 2-7 days for a 14-day cycle The specific length of these penods depends mamly on efficacy data, side effects if any, the time required to achieve maximum biological response, the maximum time required for maintenance of a biological response, and, for the off-treatment, the penod of treatment employed as noted below The treatment pattern of administering IGF-I and then stoppmg admmistration thereof is repeated until the desired maintained biological response is obtamed in the mammal In one embodiment, the same length of treatment and discontinuance of treatment is repeated and the same dosmg is used during each cycle, however, the mvention also encompasses the situation where each cycle of on and off treatment mvolves a different peπod of time and/or dosmg For example, if side effects were observed duπng the initial treatment peπod, the repeated treatment peπod and/or dosmg might be reduced, whereas if efficacy mcreases duπng the first treatment with no substantial side effects, the second peπod of treatment and/or dosmg might be mcreased The on- and off-treatment penods of tune are proportionate and interdependent, such that the penod of time when treatment is not earned out is no longer than the peπod when treatment is earned out For example, if the patient is treated for 4 days with IGF-I, he or she can be off treatment for up to 3 days, but not for 4 or more days, at that pomt the patient needs to be treated again with IGF-I In a preferred embodiment, the cycle of treatment adds up to a total of 7 days or 14 days to ease tracking of the treatment by the patients The table below illustrates this scheme On treatment Off treatment 4 days 3 days 5 days 2 days 6 days 1 day 7 days 7 days 8 days 6 days 9 days 5 days 10 days 4 days 11 days 3 days 12 days 2 days One of the purposes of the intermittent therapy with IGF-I is to maintain stable plasma levels of some of the IGF bmdmg protems to facilitate the most appropπate treatment with IGF-I Alternatively, the IGF-I may be formulated so as to have a continual presence m the blood duπng the course of treatment, as for example by being made into a long-actmg formulation, e g , by bemg covalentlv attached to a polymer such as polyethylene glycol (PEG) In this embodiment, fewer mjections could be given in each course of treatment due to the persistence of the IGF-I m the body by way of the long-actmg nature of the preparation In this embodiment, if each mjection causes an exposure of several days, the smgle mjections tailored to give exposures as descπbed above would be the regimen used If the formulation is long-actmg, the mjections are suitably given at weekly intervals or at multiples of weekly intervals Suitable examples of sustained-release preparations, which are one type of long-actmg formulation, include semi-permeable matnces of solid hydrophobic polymers containing the protein, which matπces are in the form of shaped articles, e g , films, or microcapsules Examples of sustamed-release matπces mclude polyesters, hydrogels (e g , poly(2-hydroxyethyl-methacrylate) as descπbed by Laπger et al , J Biomed Mater Res . 15 167-277 .19811 and Langer, Chem Tech , 12 98-105 [1982] or poly(vιnylalcohol)), polylactides (U S Patent No 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al , Biopolvmers. 22 547-556 [1983]), non-degradable ethylene-vmyl acetate (Langer et al , supra), degradable lactic acid-glycohc acid copolymers such as the Lupron Depot™ (injectable microspheres composed of lactic acid-glycohc acid copolymer and leupro de acetate), polylactate polyglycolate (PLGA), and poly-D-(-)-3- hydroxybutyπc acid (EP 133,988) The IGF-I also may be entrapped m microcapsules prepared, for example, by coacervation techniques or by mterfacial polymerization (for example, hydroxymethylcellulose or gelatin- microcapsules and poly-[methylmethacylate] microcapsules, respectively), m colloidal drug delivery systems (for example, posomes, albumin microspheres, microemulsions, nano-particles and nanocapsules), or in macroemulsions Such techniques are disclosed m Remington's Pharmaceutical Sciences, supra While polymers such as ethylene-vmyl acetate and lactic acid-glycohc acid enable release of molecules for over 100 days, certam hydrogels release protems for shorter time penods When encapsulated proteins remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37° C, resulting m a loss of biological activity and possible changes m lmmunogenicity Rational strategies can be devised for protein stabilization depending on the mechanism mvolved For example, if the aggregation mechanism is discovered to be mtermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifymg sulfhydryl residues, lyophilizmg from acidic solutions, controlling moisture content, using appropnate additives, and developmg specific polymer matπx compositions Sustamed-release IGF-I compositions also mclude hposomally entrapped IGF-I Liposomes containing IGF-I are prepared by methods known per se DE 3,218,121 , Epstein et al , Proc Natl Acad Sci USA. 82 3688-3692 (1985), Hwang et al , Proc Natl Acad Sci USA, 77 4030-4034 (1980), EP 52,322, EP 36,676, EP 88,046, EP 143,949, EP 142,641, Japanese patent application 83-118008, U S Patent Nos 4,485,045 and 4,544,545, and EP 102,324 Ordmaπly the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the hpid content is greater than about 30 mol % cholesterol, the selected proportion bemg adjusted for the most suitably IGF-I therapy A specific example of a suitable sustamed-release formulation is m EP 647,449 For parenteral administration, in one embodiment, the IGF-I is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypep tides. Generally, the formulations are prepared by contacting the IGF-I uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes. The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or non-ionic surfactants such as polysorbates, poloxamers, or PEG. The IGF-I is typically formulated in such vehicles at a concentration of about 0.1 mg/mL to 100 mg/mL, preferably 1-10 mg/mL, at a pH of about 4.5 to 8. Full-length IGF-I is preferably formulated at a pH about 5-6, and des(l-3)-IGF-I is preferably formulated at a pH about 3.2 to 5. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of IGF-I salts. While the IGF-I can be formulated in any way suitable for administration, the preferred formulation contains about 2-20 mg/mL of IGF-I, about 2-50 mg/mL of an osmolyte, about 1-15 mg/mL of a stabilizer, and a buffered solution at about pH 5-6, more preferably pH about 5-5.5. Preferably, the osmolyte is an inorganic salt at a concentration of about 2-10 mg/mL or a sugar alcohol at a concentration of about 40-50 mg/mL, the stabilizer is benzyl alcohol or phenol, or both, and the buffered solution is an acetic acid salt buffered solution. More preferably, the osmolyte is sodium chloride and the acetic acid salt is sodium acetate. Even more preferably, the amount of IGF-I is about 8-12 mg/mL, the amount of sodium chloride is about 5-6 mg/mL, the amount of benzyl alcohol is about 8-10 mg/mL, the amount of phenol is about 2-3 mg/mL, and the amount of sodium acetate is about 50 mM so that the pH is about 5.4. Additionally, the formulation can contain about 1-5 mg mL of a surfactant, preferably polysorbate or poloxamer, in an amount of about 1-3 mg mL. Alternatively, the formulation is suitably IGF-I dissolved at 5 mg/ml in 10 mM citrate buffer and 126 mM NaCI at pH 6. IGF-I to be used for therapeutic administration is preferably sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic IGF-I composition generally is placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle. The IGF-I ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution, or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-mL vials are filled with 5 mL of sterile-filtered 1% (w/v) aqueous IGF-I solutions, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized IGF-I using bacteriostatic Water-for-Injection. IGF-I can be administered along with a low-protein diet or with a low-protein diet in conjunction with nutrient supplements such as ketoacid supplements. In addition, the IGF-I is appropriately administered together with any one or more of its binding proteins, for example, those currently known, i.e., IGFBP1, IGFBP2, IGFBP3, IGFBP4, IGFBP5, or IGFBP6, or with the acid-labile subunit (ALS) of the IGF binding complex. Such proteins may be administered separately or as a complex with the IGF-I. The IGF-I may also be coupled to a receptor or antibody or antibody fragment for administration. The preferred binding protein for IGF-I herein is IGFBP3, which is described in U.S. Pat. No. 5,258,287 and by Martin and Baxter, J. Biol. Chem., 261 : 8754-8760 (1986). This glycosylated IGFBP3 protein is an acid-stable component of about 53 Kd on a non-reducing SDS-PAGE gel of a 125-150 Kd glycoprotein complex found in human plasma that carries most of the endogenous IGFs and is also regulated by GH. The administration of the IGF binding protein with IGF-I may be accomplished by the method described in U.S. Pat. No. 5,187,151. Briefly, the IGF-I and IGFBP are administered in effective amounts by subcutaneous bolus injection in a molar ratio of from about 0.5:1 to about 3: 1, preferably about 1 :1. In a further embodiment, depending on the chronic disorder being treated, another drug besides IGF-I or IGFBP is administered in conjunction with the IGF-I. For example, for a renal indication, it may be desirable to administer in conjunction with IGF-I other renally active molecules that promote reabsorption and retention of electrolytes such as, e.g., atrial natriuretic peptide (ANP), ANP analogs, or any variants thereof with or without receptor activity, urodilatin, human B-type natriuretic peptide (BNP), angiotension receptor antagonist, vasopressin and its analogs, and endothelin antagonists such as antibodies or peptide antagonists. One example isBQ-123 (Tharae. a/.. Life Science, 50: 247-250 .19921: JP 51-94254A published August 3, 1993; Webb et al., Biochem. Biophvs. Res. Comm.. 185: 887-892 [ 1992]), a cyclic pentapeptide that is a potent and specific blocker of endothelin A receptors and blocks only the hypertrophic activity induced by endothelin- 1, not CT-1, mouse LIF, or phenylephrine. Another example is the parent compound to BQ-123 described by Diara et al., Biochim. Biophvs. Res. Comm, 178: 132-137 (1991). Further examples include those described in EP 647,236; EP 647,449; EP 633,259 (phenyl-sulfonyl __π_ino-pyrimidine derivatives); EP 601,386 (sulfonamide compounds); U.S. Pat. No. 5,292,740 (phenylsuffon__midopyrimidines); and U.S. Pat. No. 5,270,313 (phenyl-sulfonyl- aimnopyrimidine derivatives). In addition, angiotensin-converting enzyme (ACE) inhibitors may be beneficial in conjunction with the IGF-I treatment of renal disorders. In the treatment of congestive heart failure, ACE inhibitors may be useful together with IGF-I by reducing systemic vascular resistance and relieving circulatory congestion. The ACE inhibitors include but are not limited to those designated by the trademarks Accupril (quinapril), Altace (ramipril), Capoten (captopril), Lotensin (benazepril), Monopril (fosinopril), Prinivil (lisinopril), Vasotec (enalapril), and (Si s Zestril (lisinopril). One example of an ACE inhibitor is that sold under the trademark Capoten . Generically referred to as captopril, this ACE inhibitor is designated chemically as l-[(2S)-3-mercapto-2-methylpropionyl]- L-proline. As another example of combmation therapy, for an anabolic indication, it mav be desirable to administer both IGF-I and GH to the mammal, each m effective amounts, or each m amounts that are sub-optimal but when combined are effective Preferably, such amounts are about 50 to 100 μg kg/day of IGF-I and about 0 3 mg/kg/week GH Preferably, if GH and IGF-I are admmistered together, the admmistration of both IGF-I and GH is by mjection usmg, e g , intravenous or subcutaneous means More preferably, the administration is by subcutaneous mjection for both IGF-I and GH, most preferably daily mjections It is noted that practitioners devismg doses of both IGF-I and GH should take into account the known side effects of treatment with these hormones For GH the side effects mclude sodium retention and expansion of extracellular volume (Fkkos et al , Acta Endocnnol (Copenhagen), 32 341-361 [1959], Bigheπ et al , J Chn Endo Metab. 21 361-370 [1961]), as well as hypennsuhnemia and hyperglyceπua The side effects of IGF-I are noted above Indeed, the combination of IGF-I and GH may lead to a reduction m the unwanted side effects of both agents (e g , hypoglycemia for IGF-I and hypennsulinism for GH) and to a restoration of blood levels of GH, the secretion of which is suppressed by IGF-I The IGF-I and GH, preferably the full-length IGF-I, may be admmistered separately or may be formulated together m an appropπate earner vehicle to form a pharmaceutical composition that preferably does not contain cells In one embodiment, the buffer used for formulation will depend on whether the composition will be employed immediately upon mixing or stored for later use If employed immediately after mixing, a mixture of full-length IGF-I and GH can be formulated m mannitol, glyeme, and phosphate, pH 7 4 If this mixture is to be stored, it is formulated in a buffer at a pH of about 6, such as citrate, with a surfactant that increases the solubility of the GH at this pH, such as 0 1% polysorbate 20 or poloxamer 188 The final preparation may be a stable liquid or lyophilized solid The preferred combined composition compπses IGF-I and GH m a weight ratio of IGF-I GH of between about 1 1 and 100 1 (w/w), about 005-0 3 mM of an osmolyte, about 0 1-10 mg/mL of a stabilizer, about 1-5 mgmL of a surfactant, and about 5- 100 mM of a buffer at about pH 5-6 Preferably, the osmolyte is an inorganic salt and the surfactant is nomomc More preferably, the inorganic salt is sodium chloπde or potassium chlonde, the stabilizer is phenol or benzyl alcohol, the surfactant is polysorbate or poloxamer, the buffer is sodium acetate or sodium citrate or both, and the amounts of IGF-I and GH are about 2-20 mg/mL and about 0 2-10 mg/mL, respectively, with the weight ratio of IGF-I GH bemg between about 1 1 and 50 1 Even more preferably, the amount of IGF-I is about 5-10 mg/mL, the amount of GH is about 1 -5 mg/mL, the weight ratio of IGF-I GH is about 1 1 to 4 1 , the amount of sodium chloπde is about 5-7 mg/mL, the amount of phenol is about 0 1 -3 mg/mL, the amount of benzyl alcohol is about 6-10 mg/mL, the surfactant is polysorbate m an amount of about 1-3 mg/mL, the amount of sodium acetate is about 2 5-4 mg/mL, and the amount of sodium citrate is about 0 1-1 mg/mL The following examples are offered by way of illustration and not by way of limitation The disclosures of all citations m the specification are expressly incorporated herem by reference EXAMPLE I Introduction Renal function can be enhanced by administration of IGF-I at 100 μg/kg subcutaneously each day m the morning for four days m the setting of end-stage chrome renal failure as established by Miller et al , supra However, renal function returned to the baseline level at 28 days despite ongomg, continuous treatment with IGF-I In contrast, Example I shown herem demonstrates ongomg efficacy when intermittent dosmg is given m the context of end-stage chrome renal failure Methods Five individuals over eighteen years of age with end-stage chronic renal insufficiency (ESRD), defined as a creatinine clearance less than 15 mL/mιn/1 73 m within the last six months and havmg characteπstic symptoms of ESRD, were selected for the study Patients with a single kidney or a history of malignancy were excluded from the study Patient 1 was a 71 -year-old Caucasian female with ESRD secondary to Type II diabetes mel tus Her diabetes was of 10 years duration and was complicated by retmopathy, neuropathy, and nephropathy Symptoms on admission mcluded mild intermittent nausea, pruπtus, and decreased exercise tolerance Patient 2 is a 64-year-old Caucasian female with ESRD secondary to chrome glomerulosclerosis and hypertension The patient was noted to have renal impairment approximately 5 years ago She was treated with prednisone but could not tolerate the therapy as she developed steroid-mduced psychosis She had expeπenced progressive deteπoration of renal ftmction Symptoms on admission mcluded nausea, pruπtus, edema, and decreased exercise tolerance Patient 3 is a 52-year-old Caucasian male with a history of ESRD secondary to chrome glomerulonephπtis and hypertension The patient was first noted to have mild impairment of renal function 20 years ago He was treated with steroids without any response Over the last several years he has had progressive deteπoration of his renal ftmction Symptoms at the time of admission were severe nausea, pruπtus, shortness of breath, and decreased exercise tolerance Patient 4 is a 59-year-old Caucasian female with a history of ESRD secondary to interstitial nephπtis The patient was diagnosed with Crohn's disease, requiring a partial colectomy at age 39 Unfortunately, she was left with madequate bowel and has suffered with chrome malabsorption Three years ago she was noted to have an elevated creatinine level A renal biopsy demonstrated interstitial nephπtis and she has expeπenced progressive deteπoration of renal function Symptoms at the time of admission were pruπtus, sleep disturbance, and decreased exercise tolerance Patient 5 is a 49-year-old Caucasian male with a history of ESRD secondary to autosomal dominant polycystic kidney disease The patient was diagnosed 20 years ago when his father developed renal failure Over the last 10 years he has expeπenced progressive declme m renal function Symptoms at the time of admission were pruπtus, intermittent nausea, and decreased exercise tolerance The study protocol was approved by the Human Studies Committee of Washington University Informed consent was obtamed and patients were admitted to the Washington University General Clinical Research Center (GCRC) and placed on a diet of 35 kcal/kg/day, 2 g sodium/day, and 0 8 g/kg protein/day Subjects remained on the standardized diet throughout the duration of the study Patients participated m protocols of 4 to 20 weeks m duration The first day of the protocols was designated as day 0 On day 0, measurements of blood urea nitrogen (BUN), serum Na , K + , HCO3 " , IGF-I, IGFBP 1, -2, and -3, creatinine, calcium, and phosphate were obtamed m addition to mulm and PAH clearances BUN, serum Na , K , HCO3 " , creatinine, calcium, phosphate, and glucose levels were measured on an Hitachi 747 11V1 autoanalyzer (Boehπnger Mannheim, Indianapolis, IN) IGF-I and IGFBP levels m serum were measured by Endocπne Sciences (Calabasas Hills, CA) Dunnett's multiple compaπson procedure (Miller et al , supra) was used for multiple o mpaπsons Values were considered significantly different if p < 0 05 for 2-taιled analysis The data were analyzed usmg one-way analysis of vaπance (ANOVA) (Instat, Graph Pad Software Ine , San Diego, CA) On days 1 through 4 the patients received rhIGF-I dissolved at 5 mg/ml m 10 mM citrate buffer and 126 mM NaCI at pH 6 (provided by Genentech, Ine , South San Francisco, CA) at a dose of 50 μg/kg subcutaneously once per day at 8 AM (QAM) These patients were not treated with IGF-I on days 5 through 7 and then treated again on days 8 through 1 1 and then not treated on days 12 through 14 and then treated, usmg this administration/dosing pattern for a penod of 4 to 20 weeks Blood samples were obtamed on the first and fourth day, at the beginning and end of each cycle of treatment, of each week for the first four weeks, to determme mulm and PAH clearances and IGF-I, IGFBP 1, IGFBP2, and IGFBP3 levels Results Figure 1 shows the mulm clearance for patients 1 -5 for up to 24 days m the study It can be seen that the mulm clearance progressively mcreased duπng the course of the treatment regimen of intermittent IGF-I Figure 2 shows the PAH clearance for patients 1 -5 for up to 24 days m the study It can be seen that PAH clearance also mcreased with the treatment regimen Figure 3 shows the IGF-I levels for patients 1 -5 for up to 24 days m the study It can be seen that IGF-I levels πse and fall with the intermittent treatment regimen but that IGF-I levels are maintained with each cycle of treatment Figure 4 shows the IGFBP3 levels for patients 1-5 for up to 24 days in the study It can be seen that these levels generally are stable throughout the 24 days of the study Figure 5 shows the IGFBP 1 levels for patients 1 -5 for up to 24 days m the study It can be seen that these levels generally πse with the treatment regimen Figure 6 shows the IGFBP2 levels for patients 1 -5 for up to 24 days in the study These levels πse and fall with the intermittent treatment regimen Figures 7-10 respectively show the mulm clearance patterns for patients 2-5 for a peπod of days and weeks m the study Figure 11 demonstrates the mean mulm clearance of the five patients treated for 24 days and the four patients that continue on IGF-I for up to 8 weeks The intermittent dosage treatment delayed by ten weeks the time that Patient 3, who was m the worst condition at baselme of the five patients studied, had to undergo dialysis The other four patients did not need to be subjected to dialysis The exercise tolerance for all five patients was improved The side effects expeπenced were minimized, with local untation at the site of mjection m two of the five patients studied bemg 7 a mmor effect The glomerular filtration rate (GFR) for the five patients mcreased to 12 0 mL mιn/1 73 m on day 24 of the study, an increase of 56% over baselme Most patients require dialysis when the clearance rate is below 10 0 mL/mιn/1 73 m When compared to baselme, there was a statistically significant elevation in the combined mulm clearances for patients 1 -5 when examined at days 14, 17, 21 , and 24 The symptoms and routine laboratory studies of the five patients (baselme and treatment) are provided m Tables I and II, respectively The means and standard errors on Figures 1 -6 are provided m Table III TABLE I Symptoms Symptoms Admission I Month Nausea 4/5 0/5 Pruritus 5/5 0/5 Edema 1/5 1/5 Shortness of breath 1/5 0/5 Decreased exercise tolerance 5/5 1/5 Sleep disturbance 1/5 0/5 Side Effects Local irritation not applicable 2/5 Edema not applicable 1/5 TABLE II Routine Laboratory Studies Patients 1-5 Day Na + K + Cl Bica Bun Cre Ca Pho TP Alb Hct Wbc 0 139 3.6 101 22.8 69.8 6.5 9.9 5.6 7.0 3.9 31.1 8.0 3 138 3.7 99 23.2 63.2 6.3 9.5 5.9 6.2 3.5 30.2 8.2 24 139 4.0 102 22.6 57.5 5.9 9.8 5.3 6.8 3.8 28.6 8.1 Na = Sodium K = Potassium υi Cl = Chloride I Bica = Bicarbonate Bun = Blood urea nitrogen Cre = Creatinine Ca = Calcium Pho = Phosphorus TP = Total protein Alb = Albumin Hct = Hematocrit Wbc = White blood cell count TABLE III Day 0 3 7 10 14 17 21 24 Inulin Clearance 7.7 10.8 10.2 9.8 10.9 13.9 11.4 12.0 Std. error 0.8 0.8 0.9 0.7 0.9 1.1 0.5 1.1 PAH Clearance 48.9 53.4 58.4 51.7 54.8 53.9 54.6 60.6 Std. error 10.4 15.2 11.0 12.6 15.4 13.9 13.4 16.6 IGF-I Level 170.8 291.8 153.5 338.4 144.4 276.5 137.8 303.8 Std. error 22.2 63.3 20.7 71.7 15.0 46.7 7.9 19.9 I BP-1 Level 26.3 79.5 79.8 83.8 50.9 77.5 54.4 45.9 Std. error 6.1 53.7 41.5 40.3 23.7 54.2 29.8 20.7 BP-2 Level 2004.5 2570.5 1803.0 2701.0 1749.8 2256.3 1888.8 2326.4 Std. error 809.1 1 160.7 762.9 823.7 606.2 604.3 636.0 551.1 BP-3 Level 3.7 3.5 4.1 4.0 3.6 3.4 3.7 3.8 Std. error 0.2 0.2 0.3 0.2 0.2 0.1 0.4 0.2 Summary and Conclusion IGF-I can be administered safely in an intermittent fashion to patients with symptomatic ESRD. The treatment resulted in a sustained improvement in renal function over a 4-week period with resolution of most uremic symptoms. No adverse side effects were observed in patients receiving the IGF-I in an intermittent mode. The improvement in renal function persisted throughout the administration cycle despite IGF-I levels returning to baseline after each period of inteπnittent exposure and prior to the next treatment cycle. Administration of IGF-I in an intermittent manner did not suppress IGFBP3 levels over the course of four weeks. Hence, administration of IGF-I in an intermittent fashion to patients with symptomatic ESRD can delay or obviate the need for dialysis or transplantation. EXAMPLE II Control Study A The loss of lean body mass accompanying AIDS-associated cachexia is refractory to current modes of therapy. Ten subjects with AIDS-associated cachexia with an average weight loss of 15.8 + 2.1% (range 8.3- 24.8%) were infused intravenously with low (4 μg/kg/hr) or high (12 μg/kg/hr) doses of recombinant human IGF-I formulated in citrate buffer as described in Example I for 12 hours each day over a period of 10 days following dietary stabilization. (This translates to an IGF-I dose of 48 or 144 μg/kg/day, respectively.) Protein turnover ( 13 C-leucine and 1 5 N-glycine techniques) was measured as follows: 1 C-leucine was infused on days -1 and 10. Twenty-four-hour infusions of N-glycine were performed on days -2 and 9. Nitrogen balance was measured at baseline and during the final three days of IGF-I administration. Nitrogen retention was followed throughout IGF-I infusion. Cumulative nitrogen retention was significantly positive during the first seven days of treatment (+9.52 + 4.09 g, p < 0.05), but the effect was transient. Nitrogen balance and indices of protein turnover during the final three days of treatment were unchanged compared to baseline. There was a trend toward lower (1.32+0.82 g/day vs. 3.24+1.19 g/day) and earlier (median day 6 vs. median day 10) peak nitrogen retention with high-dose than with low-dose IGF-I inftision. With repeated IGF-I administration, pre-infiision IGF-I levels increased (low dose: day 1, 151+23; day 5, 253+ 55; day 10, 249 +51 μg/L; p=0.02; high dose: day 1, 124+16; day 5, 222+26; day 10, 179+28 μg/L; p=0.02), but the increment in circulating IGF-I during infusion decreased (low dose: day 1, 284+77; day 5, 132±55; day 10, 64+7 μg/L; p=0.08; high dose: day 1, 376+42; day 5, 249+38; day 10, 256+38 μg/L; p < 0.01), producing a trend toward lower steady-state IGF-I levels. This was accompanied by declining levels of IGFBP3 (day 1, 3.09+0.21; day 5, 2.77+0.27; day 10, 2.57+0.20 mg/L; p=0.0003 for all 10 subjects together). Levels of IGFBP 1 and IGFBP2 were also significantly affected by repeated IGF-I administration. Hence, IGF-I promotes anabolism but tachyphylaxis develops rapidly. This is reported by Lieberman et al. (1993 and 1994), supra. Control Study B In this study, the utility of IGF-I was examined in immobilized patients with severe head injuries, a condition associated with profound hypercatabolism and nitrogen loss. Within 72 hours of injury, male and female patients (n=24, 18-46 years) were randomized into two groups, receiving either an IV infusion of 0.01 mg/kg/hr recombinant human IGF-I in citrate buffer as described in Example I or saline for 14 days. Serum glucose concentrations and nitrogen balance were determined on every day of treatment. The interrelationships established by measuring the plasma concentrations in samples collected prior to, during, and immediately after the infusions. In the majority of patients, free IGF-I was not measurable (<6.25 μg/L) at any time point. Glucose and insulin concentrations were comparable between the two groups throughout the study. In the 11 saline-treated patients, mean (+SE) total IGF-I was 93+13 μg/L at pre-treatment, and the patients were in negative nitrogen balance (-2.9 g/day nitrogen) during the first week. As the patients recovered, total IGF-I increased to 144+29 μg L by day 14, approaching endogenous levels in healthy adults (~200 μg/L). This increase in IGF-I did not occur until day 8 of treatment and was not associated with changes in IGFBP3, IGFBP2, or GH. However, during the second week of treatment, the saline-treated patients lost an average of 5.0 g/day nitrogen. Total IGF-I in the 13 patients on IGF-I increased from 78+14 to 466+40 μg/L by day 2. In contrast to the saline-treated group, the IGF-I-treated patients retained 1.3 g/day nitrogen for the first week. The IGF-I-treated patients only maintained total IGF-I steady state for 2 days; then IGF-I declined to 220+31 μg/L by day 14 prior to discontinuing therapy. This decline was associated with a decrease in IGFBP3 from 2.8+0.2 to 2.1+0.2 mg/L, and an increase in IGFBP2 from 275+46 to 678+145 μg/L over the 14-day period. Plasma concentrations of GH declined from 2.3+0.6 to a nadir of 0.4+0.1 μg/L on day 10 of IGF-I treatment. Furthermore, the IGF-I-treated patients lost an average of 4.9 g/day nitrogen during the second week. In conclusion, in this study to examine the utility of IGF-I in critically ill patients, infusion of IGF-I produced only a transient positive nitrogen balance in these patients with severe catabolism. In the first week the patients experienced a positive nitrogen balance, but during the second week, a negative nitrogen balance was observed. Infusion of IGF-I led to the suppression of GH and IGFBP3, and to increases in IGFBP2, resulting in enhanced clearance of total IGF-I. This study is described by Chen et al, supra. Intermittent Dosing These two studies show that for 7 days of IGF-I treatment an anabolic effect was observed which subsided after 7 days. From these results it would be expected that the maximum period of treatment using IGF-I for anabolic response would be 7 days, followed by a rest from treatment of up to 7 days. Hence, when these two type of patients are treated identically as described, except that after 7 days of treatment with IGF-I they are not treated for from 2 to 7 days, they are expected to sustain a positive anabolic effect without tachyphylaxis. EXAMPLE III Seven patients with type II diabetes were injected subcutaneously with a dose of 120-160 μg/kg twice daily with recombinant human IGF-I obtained from Chiron Corp. for 4-52 days, as described by Jabri et al, supra. Four patients exhibited comparable or enhanced, whereas three had diminished, blood glucose control when treated with IGF-I relative to that while treated twice daily with NPH insulin during the six-week control period. The occurrence of adverse side effects in all patients compelled the authors to discontinue IGF-I administration before completing the 8-week treatment period. These adverse effects included edema, mild weight gain, occasional dyspnea, bilateral jaw tenderness, arthralgias and myalgias, fatigue, tachycardia, flushing, orthostatic hypotension, and local burning at the injection site. The authors concluded that the frequency and severity of side effects associated with administering high-dose subcutaneous IGF-I continuously to obese insulin-resistant diabetic patients made it an unacceptable therapeutic agent for these patients despite its ability to produce reasonable blood glucose control in about 50% of them. intermittent dosing (3-12 days treatment, 2-10 days off treatment, 3-12 days treatment, etc., where the off- treatment period chosen is no longer than the on-treatment period utilized), their glucose levels will be lowered without the side effects observed.

Claims: 1. A method for administering insulin-like growth factor-I (IGF-I) to a mammal so as to sustain its biological response in the treatment of a chronic disorder in the mammal comprising administering a therapeutically effective amount of IGF-I to the mammal to provide an exposure to IGF-I for a period of time that provides the maximum biological response in the mammal, then discontinuing said administration for a period of time equal to or less than the time period during which the IGF-I was previously administered, then administering a therapeutically effective amount of IGF-I to the mammal to provide an exposure to IGF-I for a period of time that provides the maximum biological response in the mammal, then discontinuing said administration for a period of time equal to or less than the time period during which the IGF-I was just previously administered, and repeating this pattern of admimstration and discontinuance of administration for as long as necessary to achieve or maintain sustained biological response in the mammal. 2. The method of claim 1 wherein the mammal is a human. 3. The method of claim 1 wherein the chronic disorder is chronic renal failure. 4. The method of claim 1 wherein the chronic disorder is diabetes. 5. The method of claim 1 wherein the chronic disorder is an anabolic disorder. 6. The method of claim 1 wherein the chronic disorder is a neurological, cardiac, or immunological disorder. 7. The method of claim 1 wherein when the IGF-I is administered, it is administered at least once a day consecutively. 8. The method of claim 1 wherein when the IGF-I is a lministered, it is administered in a long- acting formulation. 9. The method of claim 1 wherein the period that provides maximum biological response in the mammal is from about three to five days and the period of discontinuance of treatment of the mammal is from about two to four days. 10. The method of claim 1 wherein the period that provides maximum biological response in the mammal is from about seven to twelve days and the period of discontinuance of treatment of the mammal is from about two to seven days. 11. The method of claim 1 further comprising administering another drug to the mammal during the course of treatment. 12. The method of claim 11 wherein the drug is growth hormone. 13. The method of claim 11 wherein the drug is atrial natriuretic peptide. 14. The method of claim 11 wherein the drug is an ACE inhibitor. 15. The method of claim 11 wherein the drug is an IGF-I binding protein or acid-labile subunit. 16. The method of claim 1 wherein the IGF-I is complexed with an IGF binding protein or acid- labile subunit. 17. The method of claim 1 wherein the IGF-I is aclministered subcutaneously or intravenously. 18. A method for treating chronic renal failure in a mammal comprising administering a therapeutically effective amount of insulin-like growth factor-I (IGF-I) to the mammal to provide an exposure to IGF-I for from about three to twelve days, then discontinuing said administration for from about two to seven days, then administering a therapeutically effective amount of IGF-I to the mammal to provide an exposure to days, and repeating this pattern of aclministration and discontinuance of administration for as long as necessary to achieve or maintain sustained renal function in the mammal, said time periods of discontinuing admimstration being for a period of time equal to or less than the time period during which the IGF-I was just previously aclministered. 19. The method of claim 18 wherein when the IGF-I is administered, it is administered for from about three to five days, and when it is not administered, it is not administered for from about two to four days. 20. The method of claim 19 wherein when the IGF-I is administered, it is admmistered for four days, and when it is not administered, it is not administered for three days. 21. The method of claim 18 wherein when the IGF-I is administered, it is administered for is from about seven to twelve days, and when it is not administered, it is not aclministered for from about two to seven days. 22. The method of claim 18 wherein when the IGF-I is administered, it is administered at least once a day consecutively. 23. The method of claim 18 wherein when the IGF-I is administered, it is administered in a sustained-release format. 24. The method of claim 18 wherein the mammal is human. 25. The method of claim 24 wherein the amount of IGF-I administered per day is about 10 μg/kg to about 160 μg/kg. 26. The method of claim 25 wherein when the IGF-I is aclministered, it is administered daily or twice daily by a subcutaneous route. 27. The method of claim 18 wherein the mammal manifests end-stage chronic renal failure. 28. The method of claim 18 wherein an effective amount of an IGF binding protein or acid labile subunit or both is administered together with the IGF-I. 29. The method of claim 18 wherein the IGF-I is complexed with an IGF binding protein or acid labile subunit.

Inventors: CLARK ROSS G, GESUNDHEIT NEIL, HAMMERMAN MARC R, MILLER STEVEN B, CLARK, ROSS, G., GESUNDHEIT, NEIL, HAMMERMAN, MARC, R., MILLER, STEVEN, B.
Applicants: GENENTECH INC, UNIV WASHINGTON, GENENTECH, INC., WASHINGTON UNIVERSITY
Application year: 1996
Main classification: A61K38
IPC codes: A61K38, A61P3, A61P9, A61P13, A61P15, A61P25, A61P37